Company intelligence / Profile preview
MMJ International Holdings
- Ownership
- Private
- Development stage
- Other
Overview
MMJ International Holdings is advancing plant-derived cannabinoid therapeutics, with its lead candidate, a soft gelatin capsule containing THC and CBD ("MMJ‑002"), receiving Orphan Drug Designation from the FDA for Huntington’s disease. The company has submitted an IND application to the FDA and is preparing to initiate a Phase 2 clinical trial targeting chorea in Huntington’s disease. Regulatory delays due to DEA restrictions have led the company to expand operations internationally while continuing U.S. regulatory engagement[4][6].
- Therapeutic areas
- Neurology
- Modalities
- Small molecule (cannabinoids)Botanical drug product (plant-derived cannabinoids)
- Industry
- Biotech
Drug pipeline
1 assetPartnerships
Beyond the preview
Go deeper on MMJ International Holdings.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MMJ International Holdings.